Requires the fee schedule for appropriate current procedural terminology and proprietary laboratory analysis codes be established and regularly updated for all mandatory biomarker precision medical testing coverage by the department of health.
This bill amends the social services law to require the Department of Health to regularly update the fee schedule for mandatory biomarker precision medical testing coverage. The bill specifically directs the department to establish pricing for services under this coverage and to keep current procedural terminology (CPT) and proprietary laboratory analysis (PLA) codes up to date. It also requires the department, within 60 days of enactment, to update the fee schedule and set pricing for any covered services not already included.
In practical terms, the measure is aimed at ensuring that reimbursement and coverage rules keep pace with evolving biomarker and precision medicine testing. By tying the fee schedule to current coding systems and requiring regular updates, the bill seeks to reduce gaps between newly available laboratory tests and the state’s Medicaid or other mandatory coverage framework. The act would take effect immediately, creating a prompt administrative obligation for the Department of Health.
The bill would amend section 365-a of the social services law, specifically paragraph (mm) of subdivision 2, by adding a new requirement that the Department of Health regularly update the fee schedule for mandatory biomarker precision medical testing coverage. It would also require the department to establish pricing for covered services and, within 60 days of enactment, update the fee schedule to include appropriate CPT and PLA codes and any covered testing not already priced. The primary affected parties are the Department of Health, laboratories, providers ordering biomarker tests, and patients relying on covered precision medicine testing, particularly within the Medicaid or related public coverage system.
Based on the bill text and the absence of recorded committee discussion or votes, the available record suggests a generally supportive policy intent focused on modernizing coverage for precision medical testing. The bill is framed as an administrative and reimbursement update rather than a controversial expansion of eligibility, which may make it broadly appealing to healthcare stakeholders. However, no formal vote history or transcript is available to confirm the level of support or opposition.
The main potential point of contention is administrative and fiscal: requiring the Department of Health to regularly update fee schedules and establish pricing could raise concerns about implementation burden, reimbursement levels, and state spending. Laboratories and providers are likely to favor the measure because it may improve payment clarity and coverage for newer tests, while budget-conscious policymakers or administrators may question the cost and operational impact of mandating frequent updates. Because there are no committee transcripts or votes provided, no specific named opponents or supporters can be identified from the record.